SEC Form 4 · accession 0001179110-18-006500
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Bolt
Officer — SVP, QA and Regulatory Affairs
Period of report
May 7, 2018
Accepted (ET)
May 9, 2018 · 7:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 parF5 | May 7, 2018 | M | 1,666 | $99.62 | A | 66,414 | D | |
| Common Stock, $.01 parF5 | May 7, 2018 | M | 4,000 | $66.25 | A | 70,414 | D | |
| Common Stock, $.01 parF5 | May 7, 2018 | M | 5,000 | $21.55 | A | 75,414 | D | |
| Common Stock, $.01 parF5 | May 7, 2018 | M | 5,000 | $23.15 | A | 80,414 | D | |
| Common Stock, $.01 parF6,F7 | May 7, 2018 | S | 1,545 | $345.2054 | D | 78,869 | D | |
| Common Stock, $.01 parF6,F8 | May 7, 2018 | S | 2,655 | $346.198 | D | 76,214 | D | |
| Common Stock, $.01 parF6,F9 | May 7, 2018 | S | 5,408 | $347.0193 | D | 70,806 | D | |
| Common Stock, $.01 parF6,F10 | May 7, 2018 | S | 2,713 | $347.9809 | D | 68,093 | D | |
| Common Stock, $.01 parF6,F11 | May 7, 2018 | S | 7,901 | $349.0553 | D | 60,192 | D | |
| Common Stock, $.01 parF6,F12 | May 7, 2018 | S | 1,000 | $350.007 | D | 59,192 | D | |
| Common Stock, $.01 parF6,F13 | May 7, 2018 | S | 1,368 | $350.9391 | D | 57,824 | D | |
| Common Stock, $.01 parF6,F14 | May 7, 2018 | S | 200 | $352.16 | D | 57,624 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F5,F1 | $23.15 | May 7, 2018 | M | 5,000 | D | May 14, 2014 | May 14, 2023 | Common stock | 5,000 | 0 | D |
| Stock Option (Right to Buy)F2,F5,F3 | $21.55 | May 7, 2018 | M | 5,000 | D | May 14, 2015 | May 14, 2024 | Common Stock | 5,000 | 0 | D |
| Stock Option (Right to Buy)F2,F5,F3 | $66.25 | May 7, 2018 | M | 4,000 | D | May 13, 2016 | May 13, 2025 | Common Stock | 4,000 | 2,000 | D |
| Stock Option (Right to Buy)F4,F5,F3 | $99.62 | May 7, 2018 | M | 1,666 | D | May 24, 2017 | May 24, 2026 | Common Stock | 1,666 | 3,334 | D |
| Stock Option (Right to Buy)F4,F3 | $134.51 | holding | — | — | — | May 15, 2018 | May 15, 2027 | Common Stock | 0 | 3,000 | D |
Explanation of responses
- F1These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $347.5600 and $348.3800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F11This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $348.5600 and $349.5000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F12This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $349.6600 and $350.3900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F13This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $350.7300 and $351.5000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F14This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $351.9700 and $352.3500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2Grant to reporting person of this option to buy the number of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- F3These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F4Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- F5Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- F6Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $344.5600 and $345.4900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $345.9500 and $346.5500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $346.5600 and $347.5500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.